首页|瑞巴派特联合艾司奥美拉唑治疗糜烂性胃炎的临床疗效

瑞巴派特联合艾司奥美拉唑治疗糜烂性胃炎的临床疗效

扫码查看
目的 对瑞巴派特联合艾司奥美拉唑对糜烂性胃炎患者的疗效进行观察,探讨其对患者胃功能、炎症指标等的影响.方法 选取 2022年 1至 12月北京市大兴区人民医院收治的 208例糜烂性胃炎患者,随机分为联药组(艾司奥美拉唑联合瑞巴派特,n=104)和单药组(艾司奥美拉唑,n=104),连续治疗 8周.比较两组疗效及安全性;治疗前后胃泌素、胃动素等胃功能指标、血管内皮功能、炎症水平以及胃黏膜核苷酸结合寡聚化结构域样受体含 pyrin 结构域蛋白 6(NLRP6)、三叶因子 2(TFF2)水平变化.结果 连续治疗 8 周后,联药组治疗总有效率为89.42%,高于单药组的76.92%(P<0.05);联药组胃泌素、胃动素、NO、降钙素基因相关肽水平均高于单药组(P<0.05),血管内皮生长因子、肿瘤坏死因子 α、白细胞介素 6、NLRP6、TFF2 水平均低于单药组(P<0.05);两组药物不良反应率差异无统计学意义(P>0.05).结论 瑞巴派特联合艾司奥美拉唑治疗糜烂性胃炎的临床效果理想,能改善患者胃功能、抑制胃损伤部位炎症水平、促进血管内皮功能修复、降低NLRP6、TFF2水平,不会提升药物不良反应.
Clinical effect of rebamipide combined with esomeprazole in the treatment of erosive gastritis
Objective To explore observe the curative effect of rebamipide combined with esomeprazole in patients with erosive gastritis,and explore its effects on gastric function and inflammatory indexes.Methods A total of 208 patients with erosive gastritis admitted to Beijing Daxing District People's Hospital were enrolled and randomly divided into combined medication group(esomeprazole+rebamipide,n=104)and single medication group(esomeprazole,n=104)between January and December 2022.After 8 weeks of continuous treatment,the curative effect and safety,changes in levels of gastric function indexes(gastrin,motilin),vascular endothelial function,inflammation,NOD-like receptor family pyrin domain containing 6(NLRP6)and recombinant trefoil factor 2(TFF2)in gastric mucosa before and after treatment were compared between the two groups.Results After 8 weeks of continuous treatment,total response rate of treatment in combined medication group was higher than that in single medication group(89.42%vs.76.92%,P<0.05).After treatment,levels of gastrin,motilin,nitric oxide and calcitonin gene-related peptide in combined medication group were higher than those in single medication group(P<0.05),while levels of vascular endothelial growth factor,tumor necrosis factor α,interleukin-6,NLRP6 and TFF2 were lower than those in single medication group(P<0.05).There was no statistically significant difference in the incidence of adverse drug reactions between the two groups during treatment(P>0.05).Conclusion The clinical curative effect of rebamipide combined with esomeprazole is significant in patients with erosive gastritis,which can improve gastric function,inhibit inflammation level at gastric injury sites,promote the repair of vascular endothelial function and reduce levels of NLRP6 and TFF2,and will not increase the adverse drug reactions.

Erosive gastritisRebamipideEsomeprazoleCurative effect

任爽、刘懿颖、李洋

展开 >

102600 北京市大兴区人民医院药济科

糜烂性胃炎 瑞巴派特 艾司奥美拉唑 疗效

2024

中华消化病与影像杂志(电子版)
中华医学会

中华消化病与影像杂志(电子版)

CSTPCD
影响因子:0.641
ISSN:2095-2015
年,卷(期):2024.14(3)
  • 14